Research programme: bispecific antibodies for pretargeting radioimmunotherapy - Xenova Group
Alternative Names: Bispecific antibodies for pretargeting radioimmunotherapy research programme - KS Biomedix Holdings; Research programme: PRIT bispecific antibodies - KS Biomedix HoldingsLatest Information Update: 28 Jul 2004
At a glance
- Originator Xenova Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Jul 2004 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
- 25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group
- 22 May 2001 Preclinical development for Solid tumours in United Kingdom (Unknown route)